AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01096667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ertuglilflozin 25 mg
Description: Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
Study NCT02476838 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hand Transplantation
Description: microvascular VCA transplant
Study NCT03612271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mGlide
Description: BP will be automatically transmitted to the providers. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg
Description: Telmisartan 20 mg once daily for eight weeks
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Description: Telmisartan 40 mg once daily for eight weeks
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Description: Amlodipine 10 mg once daily for six weeks
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Description: Telmisartan 80 mg once daily for eight weeks
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Description: amlodipine 5g once daily for eight weeks
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Description: Amlodipine 5 mg once daily for eight weeks
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Description: amlodipine 5mg once daily for eight weeks
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg
Description: Amlodipine 2.5 mg once daily for eight weeks
Study NCT01096667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ertuglilflozin 25 mg
Description: Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
Study NCT01563510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic operation
Description: Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
Study NCT01563510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open operation
Description: Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
Study NCT02817607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory testing and Biopsy
Description: Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit.
Study NCT00581607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: 62.5 mg bid for 4 weeks, then 125 mg bid
Study NCT00581607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day
Study NCT05216315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: 10 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus HDC stimulator (Newronika TM)
Study NCT05216315 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The sham group received direct current only on the ramps to generate a sensation of the effect.10 sessions
Study NCT03710928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low carbohydrate diet
Description: All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein.
Study NCT03710928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard carbohydrate diet
Description: All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein.
Study NCT04848987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Etching
Description: Etching enamel surface using phosphoric acid
Study NCT04848987 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Etching
Description: Etching enamel surface using phosphoric acid
Study NCT03649633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stress-dose Hydrocortisone plus Vitamin C
Description: Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
Study NCT03649633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo
Description: Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
Study NCT03173872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reiki Protocol Hand Placement Procedures
Description: Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
Study NCT02540603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Jupiter Full Face Mask
Description: Investigative F\&P Jupiter full face mask to be used for OSA therapy
Study NCT00107991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: etanercept 50 mg/week subcutaneous injection
Study NCT00729976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen suppository
Description: 5-10mg/Kg of ibuprofen
Study NCT00729976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Suspension
Description: 5-10mg/Kg
Study NCT03659994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Vitabeard
Study NCT03659994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04154592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humeral Head Depressor Muscle Co-Activation Training- Experimental Group
Description: In addition to the conservative treatment, humeral head depressor muscle co-activation training will be applied for 14 weeks. Participants in the coactivation group will perform the glenohumeral exercises while recruiting the pectoralis major, latissimus dorsi, and teres major muscles. To achieve this, voluntary recruitment of the pectoralis major, latissimus dorsi, and teres major will be taught prior to the demonstration of the glenohumeral exercises using visual feedback provided by EMG Biofeedback. When recruitment is correctly executed (50% of the maximum voluntary contraction signal), it should be maintained while performing the glenohumeral exercises. This will be confirmed by visualizing EMG signals during the exercise training session. During each appointment with the therapist, participants will be evaluated on their capacity to achieve the exercises while performing co-activation.
Study NCT04154592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., \& Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).~Individuals in the control group will use shoulder straps for 6 weeks after arthroscopic shoulder surgery. These patients will be referred to physiotherapy clinics 6th week. Patients between 6 and 20 weeks (a total of 14 weeks) will be admitted to the rehabilitation program according to the guideline mentioned above.
Study NCT04176835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Single-dose oxytocin will be administered intranasally
Study NCT04176835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03923192 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vistacam
Description: device for early proximal caries detection
Study NCT03923192 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Bitewing radiograph
Description: radiograph for proximal caries detection
Study NCT01442155 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Administered according to the Summary of Product Characteristics.
Study NCT01442155 — intervention group
Intervention type: BIOLOGICAL
Intervention: Oxaliplatin
Description: Administered according to the Summary of Product Characteristics.
Study NCT04422457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-DX600 PET/CT
Description: DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
Study NCT04547309 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga/18F-HER2 Affibody PET/CT scan
Description: HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
Study NCT02479763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Waveform-confirmed loss-of-resistance
Description: Using waveform analysis to confirm thoracic epidural space
Study NCT00656786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menadione Topical Lotion
Description: Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
Study NCT00656786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menadione Topical Lotion
Description: Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
Study NCT03810963 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HIIT-FES Cycling combined with Nutritional Counseling
Description: High intensity interval training functional electrical stimulation cycling for 30 minutes, three days per week for eight weeks, Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
Study NCT03810963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Counseling Only
Description: Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
Study NCT01079845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education, Dietary Counseling, and Cooking
Description: Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
Study NCT01079845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education, Dietary Counseling, and Cooking
Description: Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
Study NCT00433719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivir and efavirenz
Description: Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
Study NCT00433719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combivir and efavirenz
Description: Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
Study NCT01310257 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
Study NCT00735540 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Data summary only
Study NCT02331823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid Aminosalicylate Tablets
Description: a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
Study NCT02331823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptomycin injectable
Description: standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
Study NCT00200785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: garlic powder added to ambient water
Description: consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
Study NCT00200785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: garlic powder added to boiling water
Description: consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
Study NCT04698473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: NCPAP infants will be randomized into two different non invasive ventilation groups
Study NCT04698473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
Study NCT03559907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Parents
Description: Cooking Matters for Parents focuses on teaching parents of young children important lessons about self-sufficiency in the kitchen. Participants have the opportunity to practice fundamental lessons including knife skills, reading ingredient labels, cutting up a whole chicken, and making a healthy meal for a family of four on a budget of ten dollars. Each session includes meal preparation, didactic teaching, and sharing the meal as a group. Instructors share their education and experience and discuss how to choose healthy, affordable fruits and vegetables at the grocery store. Each week, adults take home a bag of groceries after each class so they can practice the recipes taught that day.
Study NCT03559907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime PREP
Description: Parents are trained to deliver each intervention component during mealtimes using a step-wise, behavioral activation approach. The parent-training prong of the Mealtime PREP intervention incorporates four active ingredients of behavioral activation (1. skills training; 2. goal-setting; 3. activity scheduling; and 4. activity monitoring) to help parents build a family meal routine that is enriched with techniques to promote child food acceptance. Each week, parents will take home healthy groceries to practice making healthy snacks and side dishes in the home.
Study NCT03786341 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: with auxiliary illuminator
Description: Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
Study NCT03786341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: with auxiliary illuminator
Description: Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
Study NCT04639219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan (T-DXd) by intravenous infusion
Study NCT02888756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iHIVARNA-01
Description: Therapeutic vaccination, followed by treatment interruption
Study NCT02888756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TriMix
Description: Therapeutic vaccination, followed by treatment interruption
Study NCT02888756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TriMix
Description: Therapeutic vaccination, followed by treatment interruption
Study NCT02888756 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Therapeutic vaccination, followed by treatment interruption
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg
Description: amlodipine 5g once daily for two weeks
Study NCT03713086 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabipur®
Description: 3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
Study NCT00281580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg
Description: Amlodipine 10 mg once daily for six weeks
Study NCT03780387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Felis Catus
Description: Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
Study NCT02919345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
Study NCT02919345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide 5 mg
Description: Glibenclamide 5 mg in addition to Metformin 1500 mg/day
Study NCT02111356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phinhole glasses
Description: Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
Study NCT02786511 — intervention group
Intervention type: DRUG
Intervention: Safety and efficacy assessments
Description: Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
Study NCT03924076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UHT Milk + Lactobacillus plantarum IS-10506
Description: 125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
Study NCT03924076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: UHT Milk
Description: 125 ml UHT milk given to placebo group
Study NCT03713086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies mRNA vaccine CV7202
Description: CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
Study NCT04354363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: Giving women PRP before ICSI
Study NCT02949739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle modification
Description: The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
Study NCT03343535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Lung Preservation
Description: OCS Lung Preservation
Study NCT02749266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Description: Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
Study NCT02749266 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham chiropractic adjustment
Description: Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
Study NCT01271166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
Study NCT00225758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1500 mg po daily for 26 weeks or longer
Study NCT01514435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Description: treatment for major depression
Study NCT01514435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18-Fluoro-desoxy-glucose positron emission tomography
Description: intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique.